Choroid plexus-targeted NKCC1 overexpression to treat post-hemorrhagic hydrocephalus

Cameron Sadegh  
*Harvard University*

Yong Zhang  
*Washington University School of Medicine in St. Louis*

Michael J Holtzman  
*Washington University School of Medicine in St. Louis*

et al.

Follow this and additional works at: [https://digitalcommons.wustl.edu/oa_4](https://digitalcommons.wustl.edu/oa_4)

Part of the *Medicine and Health Sciences Commons*

Please let us know how this document benefits you.

**Recommended Citation**


This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Choroid plexus-targeted NKCC1 overexpression to treat post-hemorrhagic hydrocephalus

Graphical abstract

Highlights

- CSF [K⁺] increases sharply in pediatric and adult post-hemorrhagic hydrocephalus model

- Blood triggers ChP calcium activity and NKCC1 expression/activation

- ChP-NKCC1 overexpression prevents ventriculomegaly and enhances CSF clearance

- Hemorrhagic stroke patient CSF samples revealed dysregulated CSF [K⁺] levels

Authors
Cameron Sadegh, Huixin Xu, Jason Sutin, ..., Hanno Steen, Mark L. Andermann, Maria K. Lehtinen

Correspondence
maria.lehtinen@childrens.harvard.edu

In brief
Intraventricular blood leads to increased CSF [K⁺], choroid plexus (ChP) calcium activity, and increased NKCC1 expression/activation. Elevated CSF [K⁺] reverses ChP-NKCC1 transport direction. In turn, ChP-NKCC1 overexpression reduces CSF [K⁺], enhances CSF clearance, and prevents ventriculomegaly. Thus, ChP-targeted NKCC1 gene therapy prevents key neurological sequelae of post-hemorrhagic hydrocephalus modeled in mouse.
Choroid plexus-targeted NKCC1 overexpression to treat post-hemorrhagic hydrocephalus

Cameron Sadegh,1,2,16 Huixin Xu,1,16 Jason Sutin,1 Benoît Fatou,1 Suhasini Gupta,1 Aja Pragana,1 Milo Taylor,1,5 Peter N. Kalugin,1,5,7 Miriam E. Zawadzki,1,6,8 Osama Alturkistani,4 Frederick B. Shipley,1,5 Neil Dani,1 Ryan M. Fame,1 Zainab Wurie,1 Pratik Talati,2 Riana L. Schleicher,16 Eric M. Klein,1 Yong Zhang,16 Michael J. Holtzman,12 Christopher I. Moore,11 Pei-Yi Lin,3 Aman B. Patel,2 Benjamin C. Wart,11 W. Taylor Kimberly,10 Hanno Steen,1,14 Mark L. Andermann,7,9,15 and Maria K. Lehtinen1,7,8,9,17,∗

1Department of Pathology, Boston Children’s Hospital and Harvard Medical School, Boston, MA 02115, USA
2Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
3Fetal-Neonatal Neuroimaging and Developmental Science Center, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA
4Cellular Imaging Core, Boston Children’s Hospital, Boston, MA 02115, USA
5Harvard College, Harvard University, Cambridge, MA 02138, USA
6Harvard/MIT MD-PhD Program, Harvard Medical School, Boston, MA 02115, USA
7Graduate Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA
8Graduate Program in Neurosciences, Harvard Medical School, Boston, MA 02115, USA
9Graduate Program in Biophysics, Harvard University, Cambridge, MA 02138, USA
10Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
11Carney Institute for Brain Science, Brown University, Providence, RI 02912, USA
12Pulmonary and Critical Care Medicine, Department of Medicine, Washington University, St. Louis, MO, 63110, USA
13Department of Neurosurgery, Boston Children’s Hospital, Boston, MA 02115, USA
14Precision Vaccines Program, Boston Children’s Hospital, Boston, MA 02115, USA
15Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
16These authors contributed equally
17Lead contact
∗Correspondence: maria.lehtinen@childrens.harvard.edu
https://doi.org/10.1016/j.neuron.2023.02.020

SUMMARY

Post-hemorrhagic hydrocephalus (PHH) refers to a life-threatening accumulation of cerebrospinal fluid (CSF) that occurs following intraventricular hemorrhage (IVH). An incomplete understanding of this variably progressive condition has hampered the development of new therapies beyond serial neurosurgical interventions. Here, we show a key role for the bidirectional Na-K-Cl cotransporter, NKCC1, in the choroid plexus (ChP) to mitigate PHH. Mimicking IVH with intraventricular blood led to increased CSF [K+] and triggered cytosolic calcium activity in ChP epithelial cells, which was followed by NKCC1 activation. ChP-targeted adeno-associated viral (AAV)-NKCC1 prevented blood-induced ventriculomegaly and led to persistently increased CSF clearance capacity. These data demonstrate that intraventricular blood triggered a trans-choroidal, NKCC1-dependent CSF clearance mechanism. Inactive, phosphodeficient AAV-NKCC1-NT51 failed to mitigate ventriculomegaly. Excessive CSF [K+] fluctuations correlated with permanent shunting outcome in humans following hemorrhagic stroke, suggesting targeted gene therapy as a potential treatment to mitigate intracranial fluid accumulation following hemorrhage.

INTRODUCTION

Intraventricular hemorrhage (IVH) following hemorrhagic stroke is a common cause of post-hemorrhagic hydrocephalus (PHH), an excessive accumulation of cerebrospinal fluid (CSF). Accounting for nearly a quarter of PHH cases, IVH is the leading etiology of pediatric hydrocephalus in North America and represents one of the most devastating complications of perinatal birth. Approximately 20% of infants with IVH develop PHH, and this permanent disruption of CSF homeostasis requires neurosurgical intervention to improve CSF clearance, either by endoscopic third ventriculostomy (ETV) or permanent ventricular shunting; adults with IVH have a similar rate of surgical intervention. Patients with permanent shunts require surgical procedures throughout life, which encumbers their families and strains the healthcare system. Over 80% of severe
cases develop cerebral palsy, epilepsy, or other neurologic impairments.10–11

The principal brain structure that regulates CSF, the choroid plexus (ChP), represents a promising target for the treatment of PHH. Located within each brain ventricle, the ChP forms the dominant physiologic interface between the bloodstream and CSF.12,13. The human ChP and its microvilli have a total surface area of up to 50% of the blood-brain barrier.14–16 This large ChP epithelial surface area provides unique opportunities for central nervous system (CNS) surveillance17 and regulation of CSF volume and composition, based on mechanisms that control water and ion fluxes.18,19 The ChP can be manipulated using adeno-associated virus (AAV)-based gene therapy.20–22 Targeted transduction of ChP, sometimes together with other CSF-contacting cells including ependyma, provides cell type specificity and has been shown in rodent models to improve neurologic symptoms of lysosomal storage disorders, Alzheimer’s disease, Huntington’s disease, and symptoms caused by the toxicity of chemotherapy, suggesting that the ChP is a viable target for sustained therapeutics for the CNS.23–26 Therefore, genetic manipulation of the ChP represents a favorable methodology for new therapies to correct CSF properties, including ionic homeostasis and total volume.

Multiple lines of evidence support ChP involvement in the pathogenesis of PHH.27,28 However, the ChP and CSF regulation in general have been understudied because of technical challenges and lack of reliable techniques to evaluate CSF dynamics in animal models. As a result, it is still unclear whether post-hemorrhagic CSF accumulation is a consequence of inadequate clearance, excess production (from the ChP or extra-choroidal sources), or both. A recent study demonstrated transiently increased ventricular CSF secretion (“hypercerebroventricular bleeding and subsequent ventriculomegaly.29 However, in embryonic and neonatal IVH models, the lysed red blood cells37 or maternal blood have been more frequently used, despite the potential mismatch in donor and recipient blood composition.38 Our proteomic analysis of mouse plasma obtained at different developmental stages revealed striking changes in the blood proteome including key coagulation factors (e.g., Kininogen-1 and Plasminogen) and inflammatory molecules (Figures S1A–S1G and Table S1). Further, in embryonic day (E) 14.5 mice, ICV injection of age-matched blood yielded more robust ventriculomegaly compared to blood from older mice (Figure S1H). Therefore, to model human pediatric IVH, we used ICV injections of age-matched blood. In addition, we employed a parallel donor/recipient surgical model to rapidly acquire unmodified allogeneic fetal blood from the same mouse strain (CD1), obviating the need for separating blood components with additives such as anti-coagulants which could, for example, interfere with calcium-dependent cell signaling and potentially trigger additional inflammation.

We studied mice at two ages, E14.5 and post-natal day (P)4, which generally correspond to human CNS development at early (second trimester) and late (early third trimester) gestation, respectively39 (Figure 1 A). The E14.5 model represents hemorrhage that occurs early in development (as early as 12GW in human fetus), which accounts for about 10%–20% of idiopathic hydrocephalus cases.40,41 The P4 model corresponds to the time when preterm infants are most vulnerable to hemorrhagic strokes in the germinal matrix (early third trimester) and also coincides with the typical timing of IVH. To model moderate to severe IVH (Papile grade 3 IVH42), we injected volumes of blood corresponding to approximately 50% of total ventricle volume at each age (2 μL blood at E14.5; 3–5 μL blood at P4). Ventricular blood formed solid clots inside P4 brains but remained in liquid form inside E14.5 brains (Figures S1 I and S1J). Red blood cells ultimately lysed in CSF, as expected (Figure S1K).

Here, we studied the role of NKCC1 in improved mouse models of pediatric and adult IVH with acquired ventriculomegaly. We found that AAV-mediated NKCC1 overexpression in the ChP following intracerebroventricular (ICV) blood injections restored CSF ionic homeostasis, accelerated CSF clearance, and mitigated ventriculomegaly. In contrast, expression of a phosphodeficient form of NKCC1 failed to mitigate ventriculomegaly. These data suggest that inadequate CSF clearance is the primary driver of post-hemorrhagic CSF accumulation and PHH. Our findings also support the concept of the ChP as a first line of defense to restore CSF homeostasis and a favorable gene therapy target for the treatment of acute conditions such as PHH following pediatric and adult hemorrhagic stroke.

RESULTS

Improved models of IVH using age-matched blood in mice

We modified current rodent models of embryonic and neonatal IVH to better reflect the physiologic mechanisms following the human condition. In most adult rodent models of IVH and PHH,43 autologous, fresh, and unmodified blood is used to model intraventricular bleeding and subsequent ventriculomegaly. However, in embryonic and neonatal IVH models, the lysed red blood cells37 or maternal blood have been more frequently used, despite the potential mismatch in donor and recipient blood composition.38 Our proteomic analysis of mouse plasma obtained at different developmental stages revealed striking changes in the blood proteome including key coagulation factors (e.g., Kininogen-1 and Plasminogen) and inflammatory molecules (Figures S1A–S1G and Table S1). Further, in embryonic day (E) 14.5 mice, ICV injection of age-matched blood yielded more robust ventriculomegaly compared to blood from older mice (Figure S1H). Therefore, to model human pediatric IVH, we used ICV injections of age-matched blood. In addition, we employed a parallel donor/recipient surgical model to rapidly acquire unmodified allogeneic fetal blood from the same mouse strain (CD1), obviating the need for separating blood components with additives such as anti-coagulants which could, for example, interfere with calcium-dependent cell signaling and potentially trigger additional inflammation.

We studied mice at two ages, E14.5 and post-natal day (P)4, which generally correspond to human CNS development at early (second trimester) and late (early third trimester) gestation, respectively39 (Figure 1 A). The E14.5 model represents hemorrhage that occurs early in development (as early as 12GW in human fetus), which accounts for about 10%–20% of idiopathic hydrocephalus cases.40,41 The P4 model corresponds to the time when preterm infants are most vulnerable to hemorrhagic strokes in the germinal matrix (early third trimester) and also coincides with the typical timing of IVH. To model moderate to severe IVH (Papile grade 3 IVH42), we injected volumes of blood corresponding to approximately 50% of total ventricle volume at each age (2 μL blood at E14.5; 3–5 μL blood at P4). Ventricular blood formed solid clots inside P4 brains but remained in liquid form inside E14.5 brains (Figures S1 I and S1J). Red blood cells ultimately lysed in CSF, as expected (Figure S1K). In both models, the mice matured without gross anatomical changes in skull dimension (Figures 1A and S1L), consistent with the majority of clinical cases. In the absence of a major externally identifiable PHH phenotype, we developed additional tools for detailed anatomic characterization and measurements of CSF dynamics.

MRI and ICP/infusion testing in models of IVH

We used fast-acquisition, T2-weighted magnetic resonance imaging (MRI) to assess ventricle volume in isoflurane-anesthetized mice approximately 3 weeks following injection of intraventricular blood at either E14.5 or P4 (Figure 1B). In both age groups,
intraventricular blood injection generated a nearly 2-fold increase in the volume of the lateral and third ventricles as compared to control mice, which received phosphate-buffered saline (PBS) 3 weeks following blood injection (Figures 1C and 1D). Ventricle volumes of control (PBS-injected) mice were not different from reported healthy un-injected mice of the same age. Notably, the doubling of ventricle volume was not apparent by less sensitive methods, including skull size measurements (Figure S1L), classic histology (e.g., due to variability in tissue preparation), or post-perfusion brain MRI (e.g., due to loss of intracranial pressure (ICP) that sustains ventricle size in smaller, more compliant brains), emphasizing the utility of live animal MRI for quantification of ventricular volume.

We used a miniaturized clinical CSF infusion test to study CSF dynamics in mice (Figures 1B and 1E). Values of intracranial compliance (Ci) and CSF resistance (RCSF) during infusion reflect the ability of the entire intracranial space (including brain, meninges, and CSF outflow routes) to adjust to increases in CSF volume. In our approach, a pressure sensor coupled with infusion tubing is implanted inside a mouse lateral ventricle to measure ICP and in turn calculate Ci and RCSF. CSF volume is increased by ICV infusion of artificial CSF (aCSF), causing ICP to rise and then plateau at a new level. The ICP trajectory provides a quantitative analysis of Ci, an indicator of the stiffness of intracranial constituents, which determines the rate at which ICP rises before it reaches a plateau at a new equilibrium under constant infusion. The total increase of ICP from baseline to plateau reflects CSF clearance capacity (termed “conductance,” related to the resistance of CSF exiting the ventricular system). When evaluated at 6–9 weeks, the baseline ICP values in control and IVH mice remained indistinguishable (Figure 1F), consistent with the lack of symptoms caused by elevated ICP, such as weight loss and impaired gait and posture. Nonetheless, mice that had received intraventricular blood had approximately half the intracranial compliance of control mice (Figures 1G and S1M), indicating their brains were stiffer and did not permit an increase in CSF volume as well as healthy mice, thus reaching peak ICP much faster. The stiffening of the brain is in agreement with clinical observations of scarring of ependyma and leptomeninges, causing reduced ventricular compliance in hydrocephalus. Strikingly, CSF clearance, as evaluated by conductance, was increased by 2-fold in our IVH model (Figure 1H). We can infer that for the ventriculomegaly to occur, the observed increase in CSF clearance must have been offset by excessive CSF production (“hypersecretion”) likely by extra-choroidal sources of CSF. Hypersecretion associated with increased ventricular volume is consistent with previous descriptions in humans with CHP hyperplasia and in a rat model of PHH, but the exact mechanisms leading to CSF hypersecretion remain to be elucidated.

Inflammation resulting from experimental procedures was unlikely to contribute to these findings. Microglial activation was restricted to the immediate proximity of the IVC injection site in brain parenchyma at P7 (Figure 1I). In addition, no substantial microglial changes were observed at the catheter insertion site during the approximately 30-min infusion period for the constant rate infusion test (Figure 1I). Overall, these data match prior histological analyses performed in conjunction with cannula insertion into the lateral ventricles demonstrating that the brain recovers from surgery without evidence of persistent inflammation. Taken together, our data from pediatric IVH mouse models suggest that intraventricular blood leads to mild ventriculomegaly compensated by increased CSF clearance, which mimics the expected clinical sequelae for a majority of post-IVH patients who do not develop severe symptoms of hydrocephalus.

**Lateral ventricle ChP responds rapidly to intraventricular blood**

Further experiments revealed that the ChP responds to intraventricular blood with cytosolic calcium spikes within seconds and changes in protein phosphorylation within days, consistent with a role in surveilling CSF composition. As is the case for many cell types, cytosolic calcium spikes are an early sign of activation of ChP epithelial cells. Increases in calcium activity with a role in surveilling CSF composition. As is the case for many cell types, cytosolic calcium spikes are an early sign of activation of ChP epithelial cells. Increases in calcium activity are readily seen in response to neurotransmitters in the CSF. Therefore, we evaluated ex vivo ChP calcium responses following epithelial contact with blood plasma. E14.5 ChP explants derived from FoxJ1-Cre::GCaMP6f transgenic mice were affixed to glass coverslips and incubated in aCSF to

---

**Figure 1. Intraventricular blood leads to ventriculomegaly in mouse models of pediatric PHH**

(A) Schematics of IVH models at E14.5 (modeling very preterm human infants of 12–20 gestational weeks [GWs]) and at P4 (modeling preterm human infants of 24–32 GW). Mice were affixed to glass coverslips and incubated in aCSF to evaluate conditioned media. (B) Workflow for IVH induction and hydrocephalus evaluation at E14.5 and P4. (C) Representative T-weighted MRI images (slice #16 of 20-slice series) showing ventriculomegaly in E14.5 and P4 IVH model (red arrow) vs. PBS control (white arrow). (D) Lateral ventricle volumes in E14.5 and P4 IVH models at P14 and P21, respectively. Scale bar, 5 mm. E14.5: PBS N = 9, IVH N = 11, ***p = 0.0008; P4: PBS N = 8, IVH N = 9, ***p < 0.0001. Welch’s two-tailed unpaired t test. Data are mean ± SD. (E) Schematic depicting the infusion test and data from an adult control mouse for analysis using the Marmarou model of CSF dynamics. Inset shows representative magnified view of ICP waveforms, which oscillate with the expected frequency of cardiorespiratory pulsations. (F–H) Measurements from infusion test, including baseline ICP, compliance, and capacity for CSF clearance. Coefficients of compliance and clearance were normalized with respect to the average PBS control value on each acquisition date. E14.5: PBS N = 11, IVH N = 9; P4: PBS N = 4, IVH N = 4. (F) not significant; (G) p = 0.0232 (if exclude the one outlier, *p = 0.0237); (H) ***p = 0.0002; (G) ***p = 0.0144, ***p = 0.001. All statistics in F–H were determined by Holm-Sidak method with multiple-comparison correction. Each data point represents one mouse. Data presented as mean ± SD. (I) Activated (CD68+) brain microglia (Iba1+) were restricted to site of needle track 2 days following IVH (dotted lines, left panels). No noticeable microglial activation immediately following ICP infusion through a cannula compared to naive mice (right panels). Scale = 200 μm.
Figure 2. The ChP responds rapidly to ventricular blood exposure

(A) Schematic depicting ChP explant imaging in response to blood exposure.
(B) Two-photon calcium imaging of ChP explant (FoxJ1-Cre::GCaMP6f mice) shows increased response following application of plasma. Scale bar, 100 μm. Top: 10 s prior to plasma. Bottom: 0.25 s after plasma exposure.
(C) Two-photon calcium activity of epithelial cells shown in (B), sorted by peak activity within 25 s following application of plasma. Black arrow indicates onset of plasma. Red dashed line indicates cutoff of non-responder cells (responder cells were defined as those that exceeded the cutoff of 6 standard deviations or more above the pre-stimulation mean within 25 s of stimulus exposure), indicating that 91% (987 out of 1,080) of ChP epithelial cells are sensitive to plasma.
(D) Epifluorescence calcium activity of entire ChP explant following addition of plasma (red) and aCSF (blue). Shaded color zones indicate SD (n = 7 mice for plasma, 3 for aCSF).
(E) ChP calcium activity showing peak intensity.
(F–H) IVH increased total ChP NKCC1 and pNKCC1 after 48 h. (G) E14.5: PBS N = 5, IVH N = 10, **p = 0.0012; P4: PBS N = 6, IVH N = 5, *p = 0.0285. (H) E14.5: PBS N = 5, IVH N = 10, *p = 0.0104; P4: PBS N = 6, IVH N = 5, *p = 0.0272. Welch’s two-tailed unpaired t test. Data presented as mean ± SD.

(legend continued on next page)
allow live cytosolic calcium imaging of FoxJ1-expressing ChP epithelial cells\(^{17}\) during focal blood application (Figure 2A). Cytosolic calcium levels in ChP epithelial cells rapidly increased in response to application of cell-free blood plasma (Figure 2B, Videos S1 and S2; similar data were obtained with cell-free blood serum, data not shown). Cell segmentation (using morphological filters) and extraction of calcium activity time courses confirmed that >90% of epithelial cells were activated in response to plasma (Figures 2B and 2C). This finding of simultaneous activation of nearly all epithelial cells allowed us to analyze bulk signals as a surrogate for individual cellular activities, thereby facilitating evaluation of overall ChP tissue responses to blood (Figures 2D and 2E).

**IVH induces NKCC1 expression/phosphorylation and leads to transiently elevated CSF [K\(^+\)]**

Rapid calcium responses of ChP epithelial cells were followed by increased expression of NKCC1 and robust phosphorylation and consequent activation of NKCC1 in E14.5 and P4 ChP 48 h following IVH. The phosphorylated NKCC1 (pNKCC1) to total NKCC1 ratio was not significantly changed (PBS vs. IVH = 1.000 ± 0.107 vs. 1.006 ± 0.286, all values normalized to corresponding PBS controls; Figures 2F–2H). Elevated NKCC1 activity at the ChP could increase or decrease ventricular CSF volume depending upon the direction of transport, which is determined by the combined gradients of Na\(^+\), K\(^+\), and Cl\(^-\), with changes in extracellular K\(^+\) having a strong influence due to the very low levels at baseline. We measured these ions in the CSF 48 h following IVH using the P4 age group and observed a significant, transient elevation in CSF [K\(^+\)] (Figure 2I), while the total osmolarity at each time point remained unchanged between IVH mice and controls (Figure 2J). The timing of post-hemorrhagic increases in CSF [K\(^+\)] coincided with a transient increase in ChP NKCC1 expression and phosphorylation. This finding supports the hypothesis that NKCC1 normalizes CSF [K\(^+\)] by increasing active transport of K\(^+\) (and its other substrate ions), paralleled by net diffusion of water\(^{51}\) across multiple pathways (likely including AQP1) from ventricular CSF into ChP epithelial cells\(^{18,52}\).

**Disruption of ChP epithelial calcium signaling worsens post-hemorrhagic hydrocephalus**

The instantaneous intracellular calcium responses, subsequent upregulation of phosphorylated and total NKCC1, and concurrent increase in CSF [K\(^+\)] (Figure 2) are all consistent with roles for the ChP as an immediate responder to ventricular blood and suggest that NKCC1 could mediate the observed increase in CSF clearance (Figure 1). As such, disruption of this compensatory response by the ChP would be expected to worsen IVH outcomes. We used several methods to block calcium responses\(^{53–55}\) in ChP explants following focal application of age-matched plasma (Figures S2A and S2B). These methods included (1) blocking release of intracellular calcium stores by disrupting 1,4,5-trisphosphate (IP\(_3\)) signaling with lithium chloride (LiCl) or by directly inhibiting the IP\(_3\) receptor with 2-aminoethoxydiphenyl borate (2-APB) and (2) abolishing extracellular calcium influx by chelation with ethylenediaminetetraacetic acid (EDTA) or ethylene glycol-bis-(\(\beta\)-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA). After confirming the effectiveness of these methods (Figures S2A and S2B), we tested the effect of disrupting ChP calcium activity in vivo on NKCC1 phosphorylation following IVH. We pre-treated adult mice with ICV LiCl (50 mM, 5 \(\mu\)L) 30 min prior to intraventricular blood exposure followed by measurement of pNKCC1 48 h later. LiCl pre-treatment decreased NKCC1 phosphorylation under these conditions, possibly because of a decrease in the phosphorylation of SPAK (Figures S2C and S2D), an upstream kinase known to phosphorylate NKCC1.\(^{28}\)

We next asked whether disruption of ChP epithelial cell calcium responses would impair compensatory CSF clearance in our IVH model. We pre-treated E14.5 embryos with ICV LiCl 30 min prior to intraventricular blood or PBS injection and evaluated post-natal mice for hydrocephalic phenotypes by MRI and by a CSF infusion test, as described above (Figure S2E). Mice receiving intraventricular blood that were pre-treated with LiCl had more pronounced ventriculomegaly as compared to controls, including two extreme cases with over 200-fold ventricular enlargement (Figure S2F). CSF infusion testing revealed a decreased, rather than increased, CSF clearance capacity in ICV LiCl + blood mice compared to ICV LiCl + PBS mice (Figure S2G). Baseline ICP was unaltered (LiCl + PBS 6.394 ± 1.559 mm Hg, N = 5, LiCl + IVH 6.407 ± 2.105 mm Hg, N = 8, p = 0.9900; Welch’s two-tailed unpaired t test). In cases of severe ventriculomegaly, ICP is technically difficult to ascertain (despite acquisition of long baseline recordings to identify the true baseline ICP) because of the potential for significant loss of CSF while placing the catheter. LiCl treatment alone did not affect ventricle size (LiCl + PBS: 0.91 ± 0.22 mm\(^3\), N = 7 vs. PBS alone: 1.01 ± 0.34 mm\(^3\), N = 9) or other CSF dynamics. While the exact molecular mechanisms remain to be elucidated, these findings are consistent with a severe reduction in CSF clearance due to mitigated NKCC1 phosphorylation and suggest that ChP responses to IVH may be necessary for the subsequent activation of NKCC1. These data support the importance of ChP epithelial calcium signaling for the maintenance of reduced ventricle size in the setting of IVH.

**AAV-NKCC1 tissue specificity and duration of expression**

We hypothesized that Chp NKCC1 augmentation may improve the ChP response to IVH. When delivered intracerebroventricularly at P5, AAV-NKCC1 expression, identified by its HA-tag (hemagglutinin tag) to distinguish it from endogenous NKCC1, was detected predominantly on the apical, CSF-facing surface of

---

\(^{1}\) CSF [K\(^+\)] increased 2 days after IVH and returned to baseline 4 days after IVH. *p = 0.0048. N = 5 for each condition, Welch’s two-tailed unpaired t test. Data presented as mean ± SD.

\(^{2}\) CSF osmolarity remained unchanged by IVH. N = 5 for each condition except for un-injected Day 21, where N = 3. Each data point in Figure 2 represents one mouse, except for CSF data, where each data point represents one biological replicate, and 2–3 mice were pooled in each biological replicate to reach sufficient CSF volume for performing the assay. Data presented as mean ± SD.
of ChP epithelial cells 48 h later at P7 (Figures 3A and S3). We used the AAV2/5 serotype, which, when delivered intracerebroventricularly, has tropism for ChP epithelial cells with minimal expression elsewhere in the CNS (Figures 3A, 3B, and S3A–S3H). ChP immunoblotting confirmed increases of both total NKCC1 and pNKCC1 (Figures 3C–3E). While expression of the HA-tag associated with AAV-NKCC1 remained detectable at 3 weeks, we did not observe persistently increased pNKCC1 or total NKCC1 expression compared to controls at 3 weeks and 9 weeks following IVH (Figures 3C–3E and S3D–S3H). These data suggest that the increase in NKCC1 expression by AAV is transient during the neonatal developmental period when endogenous NKCC1 expression levels are naturally lower. Transient NKCC1 overexpression was likely due to the large size of NKCC1. As development progresses, endogenous NKCC1 expression also steadily increases to eventually reach adult levels.

**ChP-targeted NKCC1 overexpression reduces ventriculomegaly in pediatric IVH models**

We hypothesized that AAV-NKCC1 would provide targeted augmentation of ChP activity in response to IVH in our models of pediatric PHH. We first introduced intraventricular blood in pups at P4 and then delivered AAV-NKCC1 or control AAV-green fluorescent protein (GFP) into the same lateral ventricle 24 h later at P5 (Figure 3F). We evaluated IVH mice receiving AAV-NKCC1 vs. AAV-GFP control by MRI (2–3 weeks later) and fluid dynamics testing (6–9 weeks later; Figure 3F). ChP NKCC1-overexpressing mice had smaller ventricles compared to their AAV-GFP-injected littermates following intraventricular blood exposure (Figures 3G–3I). Ventricle volumes of ChP NKCC1-overexpressing IVH mice were similar to those of healthy naive mice or sham controls receiving only PBS (Figure 1D), indicating that overexpression of NKCC1 fully rescued the blood-induced ventriculomegaly normally seen in IVH animals. NKCC1-overexpressing mice did not show any change in ICP. Notably, NKCC1 augmentation was accompanied by even higher CSF clearance capacity compared to GFP control mice at two months following IVH (Figures 3J and 3K). NKCC1 overexpression retained CSF [K+] at baseline levels compared to controls (Figure 3L; raw values provided in Figure S3S; age-matched, naive P7 animals: 4.36 ± 0.92 mM, P25 animals measured in the same inductively coupled plasma–optical emission spectrometry (ICP-OES) assay: 3.056 ± 0.625 mM [Figure 2I]), consistent with NKCC1 mediating CSF clearance by ion transport and an associated net movement of water. These data demonstrate that NKCC1 overexpression acutely mitigates ventriculomegaly and CSF [K+] and leads to persistently increased CSF clearance.

Supporting the concept that ChP-NKCC1 is protective in PHH, we found that an increase in baseline ChP NKCC1 availability by in utero overexpression (Figures S3I and S3J) also enabled a more favorable ventricular response to IVH at P4. We evaluated ventricle sizes (2–3 weeks later) and capacity for CSF clearance (6–9 weeks later). ChP NKCC1-overexpressing mice showed improved ventricle phenotypes in response to IVH compared to mice receiving PBS (Figures S3K–S3O). Importantly, NKCC1-overexpressing mice with IVH had ventricle volumes similar to wild-type (WT) mice receiving PBS (Figure 1D). They were also protected from blood-induced decreases in intracranial compliance (Figure S3P) in comparison to WT mice (Figure 1F) and had a consistently increased capacity for CSF clearance without changes in ICP following intraventricular blood exposure (Figures S3Q and S3R). These results suggest that following IVH, the therapeutic overexpression of NKCC1 initially facilitates ChP ion and fluid transport and is accompanied by longer term benefits that perhaps involve non-choroidal aspects of fluid handling in the brain.

We next tested the overexpression of a phosphodeficient form of NKCC1 (NT51) to determine whether NKCC1 overexpression required physiologic activation via phosphorylation. In NKCC1-NT51, serine and threonine residues located in the N-terminal phosphoregulatory domain typically required to be phosphorylated for NKCC1 activation are mutated to silent, charge-equivalent amino acids, rendering NKCC1 inactive (Figure 4A). We validated AAV-NKCC1-NT51 expression on the apical surface of ChP epithelial cells by its FLAG tag (peptide sequence DYKDDDDK) in neonatal mice (Figure 4B). We confirmed that AAV-NKCC1-NT51 augmentation did not increase pNKCC1 compared to WT AAV-NKCC1 (Figures 4C–4E). Importantly, when AAV-NKCC1-NT51 was delivered to neonates at P5, 24 h following IVH at P4, AAV-NKCC1-NT51 failed to mitigate ventriculomegaly when evaluated 3 weeks later by MRI (Figures 4F and 4G). AAV-NKCC1-NT51 also failed to facilitate CSF [K+] clearance when compared to WT AAV-NKCC1 (Figure 4H). These data demonstrate that together with increased
Figure 4. Inactive NKCC1 fails to mitigate ventriculomegaly in IVH mice

(A) Alignment of sequences in the regulatory domain of WT and NKCC1_NT51 shows residues with silent inactivating mutations in NKCC1_NT51.

(B) ChP apical localization of both WT and NKCC1_NT51, identified by HA and FLAG, respectively. Scale, 25 μm.

(C) P5 pups expressing AAV-NKCC1_NT51 had lower pNKCC1 levels than littermates expressing AAV-NKCC1_WT.

(D and E) Lower pNKCC1 (D) and lower pNKCC1/NKCC1 ratio (E) by AAV-NKCC1_NT51. AAV-NKCC1_WT N = 3, AAV-NKCC1_NT51 N = 4. Welch’s two-tailed unpaired t test. Data presented as mean ± SD.

(legend continued on next page)
CSF [K\(^+\)], NKCC1 expression and activation by upstream protein kinases is required to mitigate ventriculomegaly.

**ChP responds rapidly to IVH in vivo**

Developmental age at the time of IVH may factor into whether NKCC1 augmentation confers a beneficial response to IVH, as NKCC1 expression and phosphorylation are tightly regulated during late embryonic and early post-natal development.\(^{34}\) Therefore, we tested our model also in adult mice (8–10 weeks). We used a recently developed *in vivo* ChP imaging approach\(^{11}\) to record ChP calcium activity through a transcortical cranial window in awake, head-fixed adult mice. We adapted this surgical protocol to include the placement of an injection cannula into the contralateral ventricle for direct ICV delivery of reagents during live imaging of the ipsilateral ChP (Figures 5A, S4A, and S4B). We observed robust and rapid increases in ChP cytosolic calcium activity following intraventricular infusion of serum (Figures S5B–S5E and S4C, Video S3; similar observations followed plasma infusion, data not shown), consistent with findings in E14.5 ChP explants (Figure 2). In control experiments in which we infused acSF *in vivo* and *in vitro*, we further confirmed that the changes in calcium were not due to mechanical fluid movement or potential osmolarity changes introduced by serum or plasma (Figures S4D–S4I).

Using a cannula that allowed us to perform repeated CSF constant rate infusion tests following IVH (Figure 5F), we were able to investigate changes in CSF dynamics longitudinally after intraventricular blood exposure. This approach provided a level of temporal resolution that was not possible with our pediatric models (Figure 1). We first observed a decrease in CSF clearance capacity 3 days after intraventricular blood exposure (as expected based on clinical observations), followed by a steady increase in CSF clearance capacity over six weeks (Figure 5G).

**ChP-targeted NKCC1 overexpression prevents ventriculomegaly in a model of adult IVH**

We conducted serial live MRI scans to track ventricle size 1, 2, 3, 6, and 13 days following delivery of age-matched intraventricular blood. AAV-NKCC1 or control AAV-GFP was introduced 2 days after intraventricular blood (Figure 5H; immediately following the MRI session on Day 2) so that the severity of ventriculomegaly between the two groups was similar. We observed continuous enlargement of the lateral ventricles from Day 1 to Day 2 in both groups, consistent with previous studies in adult rodent models.\(^{27,28}\) By Day 3, only 24 h following AAV injection, the mice that received AAV-NKCC1 demonstrated a reduction in lateral ventricle volumes (Figures 5I and 5J). Importantly, these AAV-NKCC1 mice maintained the reduction in ventricle volumes over 2 weeks following intraventricular blood exposure, as compared to control animals (Figure 5J), suggesting sustained prevention of ventriculomegaly attributable to NKCC1 overexpression. Collectively, the results of experiments using this adult model of IVH validate the utility of AAV-NKCC1 to target ChP epithelial cells as a possible gene therapy for PHH and broaden its potential applicability across pediatric and adult ages.

**Identification of CSF ionic disequilibrium following PHH in humans**

Some of the observations in our animal models lead to specific predictions on how CSF composition might be altered in the human condition. CSF samples from adult patients with aneurysmal subarachnoid hemorrhage (aSAH) were acquired from a published prospective single-center cohort study.\(^{58,59}\) These patients were afflicted by hemorrhagic stroke due to the acute rupture of an intracranial aneurysm, with subsequent IVH and acute PHH that was treated by placement of an ICV catheter (clinically referred to as an external ventricular drain). CSF was collected at 3–6 day intervals between serial samplings for up to 16 days, totaling 54 unique CSF samples from 20 patients. The outcomes were recorded as either resolution of hydrocephalus (ICV catheter removal) or persistence of hydrocephalus (permanent shunt placement; Figures 6A and 6B). Patient demographics, illness severity, and time of collection were similar between the two groups (Figures S5A–S5D).

We observed CSF hypo-osmolarity in 60% of patients (mean ± SEM; 201 ± 16 mEq/L) despite the presence of normal serum osmolarity measurements (acquired in the same patients; Figures 6C and 6D), a phenomenon not reported previously and possibly reflecting failure of CSF ionic homeostasis following IVH. To take total osmolarity into account, we defined relative CSF [K\(^+\)] (mEq/L) as a percentage of total osmolarity (mEq/L). We found that, although absolute CSF [K\(^+\)] remained within normal limits for all patients (Figure 6E) and showed no correlation to initial IVH volume (Figure S5E), the relative CSF [K\(^+\)] was significantly higher in patients requiring shunt surgery vs. those whose hydrocephalus had resolved (1.20% vs. 1.06%, \(p < 0.05\); Figure 6F). This finding is consistent with the presence of elevated CSF [K\(^+\)] observed in our mouse IVH models (Figures 2I and 2J). Patients requiring shunting also displayed a wider range of relative CSF [K\(^+\)], possibly reflecting a reduced capacity for potassium homeostasis (Figures S5F–S5I). Therefore, CSF [K\(^+\)] and osmolarity changes may be informative metrics for CSF ionic disturbances and an indirect assessment of the ChP capacity for maintaining CSF homeostasis. Several anatomic, clinical, and radiographic factors are also associated with the need for permanent shunt surgery following aSAH,\(^{61}\) but none of these factors correlated with outcomes in our cohort of patients (Figures S5J–S5O). Collectively, our data indicate that the CSF [K\(^+\)] ionic disturbance observed in mouse models has direct translational implications and suggest that ChP management of CSF [K\(^+\)] levels might correlate with surgical need in the management of PHH.

---

\(F\) and \(G\) Representative T2-MRI images and quantification of ventricular volume in IVH mice treated with AAV-NKCC1_WT (purple arrows denote ventricles) or AAV-NKCC1_NT51 (black arrows denote ventricles). Scale, 2 mm. IVH + AAV-NKCC1_WT, \(N = 13\); IVH + AAV-NKCC1_NT51 \(N = 11\). ***\(p = 0.0001\). Welch’s two-tailed unpaired t test. Data presented as mean ± SD.

\(H\) CSF [K\(^+\)] was higher in IVH mice treated with AAV-NKCC1-NT51 compared to mice treated with WT AAV-NKCC1 3 days following IVH. WT AAV-NKCC1: \(N = 3\) (pooled across 10 pups); AAV-NKCC1-NT51: \(N = 6\) (pooled across 16 pups), \(^{*}\(p = 0.0112\). Welch’s two-tailed unpaired t test. Data presented as mean ± SD.
Figure 5. Adult mouse model of PHH mirrors key aspects of pediatric PHH and responds to ChP-NKCC1 therapy
(A) Schematic depicting devices and surgical implantation for in vivo ChP live-imaging with two-photon microscopy.
(B and C) Calcium responses to serum in ChP epithelial cells (FoxJ1-Cre::GCaMP6f mice) in vivo. Scale bar, 100 μm.
(D and E) Representative fluorescence intensity trace with serum infusion and quantification of peak intensity. aCSF N = 4, serum N = 3. *p = 0.0318. Welch’s two-tailed unpaired t test. Data presented as mean ± SD.
(F) Schematic depicting adult IVH serial infusion test post-IVH.
(G) Adult CSF clearance capacity post-IVH measured by infusion test. Naive: N = 3, 3 days: N = 5, 21 days: N = 5, 46 days: N = 6. **p = 0.0091, **p = 0.0061. Welch’s two-tailed unpaired t test. Data presented as mean ± SD.
(H) Schematic depicting the therapeutic approach in adult PHH model and the time course of serial MRI.
(I) Representative T2-MRI images showing rapid reversal of ventriculomegaly in adult PHH model by ChP-NKCC1 overexpression. AAV-GFP was used as control. Scale, 5 mm.
(J) Relative ventricular volume in adult PHH mice with AAV-NKCC1 treatment or control. For each mouse, the ventricular volumes on different days were normalized to the value of Day 2 post-IVH, immediately prior to AAV transduction. N = 4, "p < 0.05 (Day 3: p = 0.0138; Day 6: p = 0.0386; Day 13: p = 0.0152). Data analyzed by multiple t test and corrected for multiple comparisons using Holm-Sidak method. Each data point represents one mouse.
DISCUSSION

There is a dire need for new and durable treatments for the various etiologies of pediatric and adult PHH. We hypothesized that the ChP is an amenable treatment target that has a central role in rapidly restoring CSF dynamics following IVH. Here, we demonstrate a candidate ChP therapy based on overexpression of NKCC1 that decreased brain ventricular volume following IVH and prevented some of the most salient clinical features of PHH observable in mice (Figure 7). This therapeutic approach emerged from experiments using new modified mouse models of PHH and newly adapted methods to image ChP epithelial responses following blood exposure, quantify the changing intracranial capacity for CSF clearance, and specifically target the ChP using AAV to distinguish its contributions to CSF homeostasis from extra-choroidal sources.

While the ChP is commonly simply described as the major source of CSF, our work (see also Xu et al. 34) reveals a more versatile role for the ChP, with the notable ability to bidirectionally transport solutes and thereby control net movement of water in either direction across the epithelia. Our therapeutic target, NKCC1, is a well-studied ion cotransporter with a stoichiometry of Na⁺:K⁺:2Cl⁻ that is highly expressed at the apical membrane of ChP epithelial cells. Among the transported ions, CSF [K⁺] likely plays a critical role in determining NKCC1 transport directionality, as the K⁺ concentration in the CSF is typically very low and predicted to rise as a consequence of red blood cell lysis following a bleed. Indeed, acute increases in spinal CSF [K⁺] were previously found in samples from human neonates with IVH. 63

Time- and tissue-specific NKCC1 phosphorylation is required for ChP-mediated CSF volume homeostasis following IVH. ChP NKCC1 is phosphorylated at early time points, coincident with increased CSF [K⁺] during the acute phase of IVH, when CSF clearance is at a minimum and likely insufficient. To specifically assess choroidal NKCC1 contributions to ventricular CSF...
volume and ionic composition, we targeted overexpression of NKCC1 to ChP epithelia with AAVs and measured an increased post-IVH CSF clearance capacity and normalization of ventricle volume and CSF [K⁺]. AAVs provide more specificity compared with pharmacologic targeting of NKCC1, which would also affect neurons, glia, and leptomeningeal vasculature in addition to ChP epithelia. To control for off-target or dominant negative effects following AAV transduction, we tested an inactivated form of NKCC1 (AAV-NKCC1-NT51), which harbors silent mutations in the N-terminal phosphoregulatory domain and showed that this NKCC1-NT51 failed to mitigate ventriculomegaly. These findings indicate that choroidal NKCC1-mediated homeostasis is beneficial following IVH and can be augmented with targeted gene therapy. A striking corollary to these findings is that they point to extra-choroidal site(s) as likely dominant source(s) of CSF in the acute setting of hemorrhage.

We adapted the best available clinical diagnostic tools such as in vivo brain MRI, ICP measurements, and the constant rate infusion test to mice to investigate changes in CSF dynamics following IVH. Accordingly, these data offered insights that could have gone unnoticed using histologic methods or isolated measurements of ICP. With repeated CSF infusion tests on the same group of post-IVH mice over a time course of several days to weeks, we confirmed that ICP was normal despite reductions in intracranial compliance, which is consistent with a model of “compensated” and asymptomatic PHH. We also identified a temporarily reduced capacity for CSF clearance within days after IVH, consistent with either acute obstructive hydrocephalus or

Figure 7. ChP compensatory actions in PHH
(A) Two scenarios of ChP activities following IVH. Upper panels: The ChP responds to blood with acute calcium activation. After 48 h, CSF [K⁺] increases. With elevated CSF [K⁺], NKCC1 activation leads to net flux of ions and osmotically obliged water movement from CSF into ChP, resulting in compensated PHH characterized by mild ventriculomegaly and enhanced CSF clearance capacity. Lower panels: AAV-mediated overexpression of NKCC1 enhances the total amount of Na⁺-K⁺-2Cl⁻ cotransport, preventing ventriculomegaly.
(B) Mouse and human developmental timelines.
extra-choroidal CSF hypersecretion lasting one or more weeks, as previously reported in rats.\textsuperscript{28} This implies that there might be a critical and short window of opportunity to improve and hasten this compensatory response in rodent models, and perhaps a slightly different window for clinical care.

Comparing the clinical burden of IVH and mouse models may provide some insights. Humans take 1–2 weeks to clear IVH, whereas mice were able to accomplish this in 2–4 days with variable degrees of clot formation (see Figure S1) despite having a higher blood/ventricle volume ratio than in most human cases. The extent of IVH is a known negative prognostic indicator\textsuperscript{66}; in some settings, surgical hematoma clearance might be considered beneficial.\textsuperscript{67–70} Therefore, the persistence of ventricular blood in humans might explain subsequent clinical “decompensation” in contrast to the mouse model. The resultant CSF ionic disequilibrium might benefit from prolonged ChP-mediated CSF clearance. To begin to examine the extent and duration of CSF ionic disequilibrium, we acquired human ventricular CSF samples from a previously studied cohort with acute PHH. We found (1) prolonged CSF ionic disturbance in humans, suggesting a potentially wider therapeutic window of up to 2 weeks; (2) perturbations in CSF osmolarity and relative \([\text{K}^+]\) that are consistent with our model of \(\text{K}^+\)-driven ionic homeostasis; and (3) possible prognostic features of CSF composition. Using serial sampling of ventricular CSF in patients, we confirmed a prolonged duration of CSF hypo-osmolarity and relatively elevated \([\text{K}^+]\) up to 2 weeks after the onset of hemorrhage. We also observed relatively higher and more fluctuating CSF \([\text{K}^+]\) in those patients that eventually required permanent ventricular shunt placement compared to those who recovered. These data may reflect either an excessive IVH burden or the insufficiency of ChP-driven counter-regulatory mechanisms over time.

Our study supports the concept that the ChP acts as an immediate responder to intraventricular blood by boosting CSF clearance capacity in the acute phase of IVH when CSF clearance is at its nadir and that this NKCC1-dependent mechanism can be targeted by AAV therapy to achieve benefits in pediatric and adult models. AAV-NKCC1 expression was transient in our study, likely due to the large size of the transgene. This feature may help focus the benefits of NKCC1 overexpression to the critical time immediately following IVH while also helping to limit any potentially undesirable long-term consequences of the approach. The ChP might not meaningfully contribute to CSF clearance at late stages of PHH and in fact may worsen symptoms when CSF \([\text{K}^+]\) normalizes. Accordingly, subtotal ablation of the ChP in this chronic setting (ETV combined with ChP cauterization; ETV/CPC) helps avoid permanent ventricular shunt surgery in certain patients.\textsuperscript{5} However, the youngest patients with PHH (<6 months) appear to have a low rate of success with combined ETV/CPC,\textsuperscript{71} underscoring a clinical need for alternative and individualized treatment options. Gene therapy applied alone or paired with existing short-duration treatment options (e.g., CSF removal by lumbar or trans fontanelle aspiration) may ultimately reduce the need for permanent shunting, improve clinical outcomes and quality of life, and thus reduce the burden of PHH on patients and the medical system. AAV therapy is particularly appealing for PHH because of the clinical feasibility for direct surgical access for local AAV administration to the ventricular system and to the ChP.

In addition to the ChP, tissues contributing to CSF clearance include various lymphatic pathways (dural/meningeal), cranial nerves, spinal nerve roots, major blood vessels traversing the skull base, and trans-venous pathways (arachnoid granulations).\textsuperscript{72} Recent findings specifically implicate lymphatic drainage in clearing erythrocytes and iron in the context of IVH,\textsuperscript{72} suggesting that this pathway might complement the role of the ChP in homeostasis following IVH. Our constant rate infusion test incorporates all CSF clearance routes and therefore leaves open the possibility that longer-term changes in CSF clearance might also be mediated by lymphatic pathways. While ChP-targeted NKCC1 gene therapy successfully rescued elevations in \([\text{K}^+]\) and ventriculomegaly in mice exposed to intraventricular blood, future therapies may benefit from targeting both ChP (acute) and lymphatic (chronic) pathways of CSF clearance. In pediatric cases, however, the ChP may be a more important target, as studies in animal models have shown a lack of mature meningeal lymphatics until later stages in development (e.g., P12 in mice and P7 in rats).\textsuperscript{74,75}
ACKNOWLEDGMENTS

We thank the Lehtinen, Andermann, and Warf labs for helpful discussions; Kai Kaila and Biff Forbush for discussions relating to NKCC1; Nancy Chamberlin for critical reading and editing of the manuscript; Chintefi Chen and BCH IDDRC Cellular Imaging Core; Janelle Lestrade, Yaotang Wu, Michael Marcondes-trigiano, Kristina Pelkola, and BCH Small Animal Imaging Laboratory; BCH viral core; and the University of Pennsylvania Vector Core. This work was supported by the William Randolph Hearst Fund (H.X.); NIH T32 HL110862 and an OFD/STREG/OTREC Faculty Development Fellowship Award (R.M.F. and N.D.); the Harvard College Research Program (M.T.); NIH T32 HL007901 and F30 DK131642 (P.N.K.); NIH T32 GM007753 and T32 GM144273 (P.N.K. and M.E.Z.); an American Heart Association Pre-doctoral Fellowship (M.E.Z.) and the Little Giraffe Foundation (M.E.Z. and M.K.L.); the NSF Graduate Research Fellowship Program (F.B.S.); a Reagan Sloane Research Internship (N.D.); NIH F31 NS115389 (E.M.K.); NIH R01 AI130591 and R55 HL145242 (M.J.H.); NeuroNex/NSF 1707352 and a Korn family gift (C.I.M.); NIH R00 AI152179 (H.S.); NIH DP1 AT010971 (M.L.A.); a Hydrocephalus Association Discovery Science Award, the Pediatric Hydrocephalus Foundation, the Human Frontier Science Program #RGP0063/2018 (M.K.L.), a Pappendick Family Therapeutic Acceleration Award and the Translational Research Program, NIH R01 NS088566, NIH129823, and the New York Stem Cell Foundation (M.K.L.); NIH RF1 DA048790 (M.K.L. and C.I.M.); BCH IDDRC 1U54HD090255, and BCH viral core P30EYO12196. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or NIH.

AUTHOR CONTRIBUTIONS


DECLARATION OF INTERESTS

M.K.L., R.M.F., C.S., and H.X. are co-inventors on a provisional patent application related to this manuscript.

INCLUSION AND DIVERSITY

One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. One or more of the authors of this paper received support from a program designed to increase minority representation in their field of research.

Received: August 16, 2022

Revised: January 17, 2023

Accepted: February 13, 2023

Published: March 8, 2023

REFERENCES


## STAR METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-NKCC1</td>
<td>Abcam</td>
<td>ab59791; RRID: AB_944433</td>
</tr>
<tr>
<td>Rabbit anti-pNKCC1</td>
<td>EMD Millipore</td>
<td>ABS1004; RRID: N/A</td>
</tr>
<tr>
<td>Rabbit anti-GAPDH</td>
<td>Sigma</td>
<td>G9545; RRID: AB_796208</td>
</tr>
<tr>
<td>Mouse anti-HA</td>
<td>Abcam</td>
<td>ab130275; RRID: AB_11156884</td>
</tr>
<tr>
<td>Rat anti-HA</td>
<td>Roche</td>
<td>11867423001; RRID: AB_390918</td>
</tr>
<tr>
<td>Rabbit anti-FLAG</td>
<td>Abcam</td>
<td>ab1182; RRID: AB_298215</td>
</tr>
<tr>
<td>Rabbit anti-Iba1</td>
<td>WAKO</td>
<td>019-19741; RRID: AB_839504</td>
</tr>
<tr>
<td>Rat anti-CD68</td>
<td>Abcam</td>
<td>ab53444; RRID: AB_869007</td>
</tr>
<tr>
<td>Bacterial and virus strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AAV2/5-NKCC1</td>
<td>Modified from Somasekharan et al.\textsuperscript{57}</td>
<td>Addgene plasmid #49077</td>
</tr>
<tr>
<td>AAV2/5-NKCC1-NT51</td>
<td>Modified from Somasekharan et al.\textsuperscript{57}</td>
<td>Addgene plasmid #49061</td>
</tr>
<tr>
<td>AAV2/5-GFP</td>
<td>Boston Children’s Hospital viral core, IDDRC</td>
<td>N/A</td>
</tr>
<tr>
<td>Biological samples</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human CSF</td>
<td>Massachusetts General Hospital</td>
<td>N/A</td>
</tr>
<tr>
<td>Chemicals, peptides, and recombinant proteins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraformaldehyde</td>
<td>Sigma</td>
<td>P6148</td>
</tr>
<tr>
<td>EGTA</td>
<td>Sigma</td>
<td>E3889</td>
</tr>
<tr>
<td>BAPTA-AM</td>
<td>Tocris</td>
<td>2787</td>
</tr>
<tr>
<td>2-APB</td>
<td>Tocris</td>
<td>1224</td>
</tr>
<tr>
<td>LiCl</td>
<td>Sigma</td>
<td>203637</td>
</tr>
<tr>
<td>Clarity\textsuperscript{TM} Western ECL Substrate</td>
<td>BioRad</td>
<td>170-5060</td>
</tr>
<tr>
<td>Deposited data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood proteomics</td>
<td>ProteomeXchange Consortium via the PRIDE partner repository</td>
<td>PXD039738</td>
</tr>
<tr>
<td>Experimental models: Organisms/strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD-1 IGS Mouse (referred to as CD-1)</td>
<td>Charles River Laboratories</td>
<td>Strain code: 022</td>
</tr>
<tr>
<td>FoxJ1-CRE</td>
<td>Zhang et al.\textsuperscript{76}</td>
<td>N/A</td>
</tr>
<tr>
<td>A955D(RCL-GCaMP6f)-D</td>
<td>Jackson Laboratory</td>
<td>028865; RRID:IMSR_JAX:028865</td>
</tr>
<tr>
<td>Software and algorithms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prism</td>
<td>GraphPad</td>
<td>v7</td>
</tr>
<tr>
<td>Fiji/ImageJ</td>
<td>Schindelin et al.\textsuperscript{77}</td>
<td><a href="http://imagej.net/Fiji;https://imagej.nih.gov">http://imagej.net/Fiji;https://imagej.nih.gov</a></td>
</tr>
<tr>
<td>ZEN Black/Blue</td>
<td>Zeiss</td>
<td>N/A</td>
</tr>
<tr>
<td>AMIDE</td>
<td><a href="https://amide.sourceforge.net/">https://amide.sourceforge.net/</a></td>
<td>N/A</td>
</tr>
<tr>
<td>MATLAB</td>
<td>Mathworks</td>
<td>R2019b</td>
</tr>
</tbody>
</table>

## RESOURCE AVAILABILITY

### Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Maria K. Lehtinen, maria.lehtinen@childrens.harvard.edu.
Materials availability
The AAV-NKCC1-NT51 plasmid was generated from Addgene product #49061. The YFP sequence was removed to reduce the total size of insert, and the coding sequence was cloned onto an AAV backbone supplied by Vector Core at University of Pennsylvania (pENN.AAV.CMV.sRbG [no intron]). All reagents are available from the lead contact.

Data and code availability
1. Data availability: Blood proteomics data are summarized in the supplemental information and the mass spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD039738. Original western blots reported in this paper will be shared by the lead contact upon request.
2. Code availability: All code used in this study is available on GitHub. https://github.com/LehtinenLab/Xu-Sadegh-2023.
3. Availability of other source data and any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animal studies
All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committees of Boston Children’s Hospital. Animals were housed in a temperature-controlled room on a 12-h light/12-h dark cycle and had free access to food and water. Mouse lines used include FoxJ1-Cre,76 Ai95D (Jax# 02410578), and CD-1 (Charles River Laboratories).

Mouse CSF samples
CSF was collected by inserting a glass capillary into cisterna magna and processed as described.79 It was visually examined for purity, and samples were centrifuged at 10,000 g for 10 min at 4°C prior to immediate analysis or storage at −80°C.

Human CSF samples
Human CSF samples were collected from external ventricular drains at Massachusetts General Hospital, centrifuged at 2000 x g for 15 min at 4°C and frozen at −80°C until analysis. Demographic, imaging, and clinical outcomes were collected from the medical record and de-identified for research purposes.

Plasma collection for proteomics using data-dependent acquisition (DDA)
Fresh blood was obtained from the jugular vein of E14.5 embryos. Adults (8 weeks) and P4 pups were anesthetized with ketamine/xyazine (dose, route), or ice, respectively, thoracotomized, and atrial blood was gently collected in EDTA coated glass microcapillary tubes (Drummond 0.4mm). Centrifugation was performed twice for 10 min at 5,000 g/rcf at 4°C and plasma was extracted from the supernatant. Only samples with yellow to salmon color were included; pink/red colored samples indicative of red blood cell lysis were discarded. Plasma samples were stored at −80°C until processing in LC/MS.

METHOD DETAILS

Mass spectrometry
Plasma samples were processed with an MStern blotting protocol developed as described.80,81 In brief, 1 μL of plasma (approximately 50 μg of protein) was mixed in 100 μL of 8 M urea buffer. Cysteine residues were reduced using a final concentration of 10 mM of dithiothreitol and then alkylated with a final concentration of 50 mM of iodoacetamide. 15 μg of proteins were loaded on to a 96-well plate with a polyvinylidene fluoride membrane at the bottom (Millipore-Sigma), previously activated with 70% ethanol and primed with 8M urea buffer. Trypsin digestion was performed onto the membrane by incubation with the protease for 2 h at 37°C. Resulting tryptic peptides were eluted with 40% acetonitrile/0.1% formic acid. A C18 clean-up of the samples was realized using a 96-well MACROSPIN C18 plate (TARGA, NestGroup) and stored at −20°C before LC/MS analysis. Samples were analyzed using a nanoLC system (Ekssigent) coupled online to a Q Exactive mass spectrometer (Thermo Scientific). From each sample, 1 μg peptide material was separated using a linear gradient from 98% solvent A (0.1% formic acid in water), 2% solvent B (0.1% formic acid in acetonitrile) to 40% solvent B over 45 min. The mass spectrometer was operated in DDA mode, selecting up to 12 of the most intense precursor ions for further MS/MS fragmentation. Label-free protein quantitation analysis employed MaxQuant 1.5.3.30.82,83 Raw data were downloaded and used to build a matching library and searched against the UniProt Mouse reviewed protein database. Standard search settings were employed with the following modifications: Max missed cleavage 3; fixed modification Carbamidomethylation (C); variable modification Oxidation (M)44. A revert decoy search strategy was employed to filter all proteins and peptides to <1% FDR.
Headpost, cranial window, and ICV canula placement
Mice used for in vivo two-photon imaging (8–20 weeks) were outfitted with a headpost and a 3 mm cranial window, as previously described. In addition to the trans-frontal bone cranial window, a contralateral trans-occipital approach to cannula insertion was developed to enable simultaneous ICV injections and two-photon imaging. The trans-occipital injection cannula was inserted through a drill hole placed in the superior- and lateral-most border of the suboccipital bone and advanced to a lateral ventricle target (stereotaxic coordinates: 0.4 mm posterior to bregma, 1.0 mm lateral to the midline, and 2.0 mm in depth from the brain surface). A dummy cannula (stylet that has the same diameter as the inside of the cannula and helps prevent CSF leakage or infection) was inserted and held in place with a screwcap to prevent infection and tissue growth into the cannula. This dummy cannula was removed prior to ICV injections. The steel cannula was then fixed to the titanium headpost and cranial window using dental cement.

Calcium imaging and analysis
Two-photon microscopy (Olympus FVMPE-RS two-photon microscope; 30.0 frames/s; 512 x 512 pixels/frame) was used to record calcium activity in ChP explants or in vivo from mice expressing GCaMP6f in epithelial cells (in FoxJ1-Cre::Ai95D mice). Imaging and analyses were performed as described with a 25× magnification, 8 mm working distance objective. Laser power measured below the objective at 940 nm was 50–60 mW, using a Mai Tai DeepSee laser (Spectra-Physics). Plasma (using citrate as anti-coagulant instead of EDTA, same protocol as described above) was delivered to explants by topical application from a glass capillary needle and serum was delivered to the lateral ventricle of live mice during imaging through the injection cannula. Serum was prepared by collecting blood using the same approach as described above, incubating on ice for 30 min and then centrifuging for 10 min at 5,000 g twice to separate the supernatant. For infusions via microinjection cannulas during in vivo two-photon imaging, approximately 30 µL aCSF or serum was delivered by syringe pump at a rate of 5 µL/min. Chemicals used on explants include: LiCl (30 mM × 15 min), BAPTA-AM (5 mM), 2-APB (50 µM), EGTA (0.5 mM), and EDTA (by collecting blood into EDTA-coated tubes; Cat# BD 365974).

ICV injections
Timed pregnant mice (E14.5) were anesthetized with isoflurane and kept warm. Following laparotomy, AAV solution or age-matched whole blood was delivered into the lateral ventricle of each embryo (located visually) with glass capillary pipettes at rate of 0.5–1 µL/s. Due to the time constraints of blood clotting inside the glass capillary pipettes, the total time for donor acquisition and recipient injection of whole blood into each embryo was 15–30 s. The uterine horns were returned to the abdomen and the incisions sutured. P4 pups were anesthetized by hypothermia and adults by isoflurane. An incision was made along the midline of the scalp to expose the skull and a 26G needle (pups) or hand drill (adults) was used to pierce the skull directly above the lateral ventricle. AAV solution or age-matched whole blood was delivered into the lateral ventricle through the piercing using glass capillary pipettes. Skin incisions were closed with suture and Vetbond (3M).

Potassium and osmolality measurements
Potassium in 5–7 µL of mouse CSF and 10–20 µL of human CSF was measured by ICP-OES by Galbraith Laboratories, Inc (Knoxville, TN, USA). Osmolarity of CSF samples was measured with a Wescor VAPRO vapor pressure osmometer. In mouse studies, 5 µL of CSF was first diluted with 10 µL ddH2O. 10 µL of the diluted sample was loaded to the osmometer, ddH2O was used to determine blank value, and the osmolarity of CSF was calculated by (sample value – ddH2O value) in triplicate. 10 µL human CSF was used without dilution.

Blood cell lysis
CSF was collected from adult mice as described above. Whole blood or purified red blood cells were collected from the same donors by cardiac puncture with a 22G needle. To purify red blood cells, 500 µL of whole blood was mixed with 50 µL 3.2% sodium citrate and centrifuged at 1,000 g for 10 min at 4 °C. Following washes with 1 mL sterile PBS in triplicate, samples were resuspended in 500 µL sterile PBS. 5 µL whole blood or purified red blood cells were mixed with 10 µL CSF, allowed to settle, and then incubated at 37 °C with images taken at the start and after 24 and 48 h of incubation.

Immunohistochemistry
Postnatal animals were perfused with PBS followed by 4% paraformaldehyde (PFA). The brains were quickly dissected and post-fixed with 4% PFA overnight. Samples were cryoprotected and prepared for embedding at 4 °C with 10% sucrose, 20% sucrose, 30% sucrose, 1:1 mixture of 30% sucrose and OCT (overnight), and OCT (1 h on ice). Samples were frozen in OCT. Cryosections were blocked and permeabilized (0.3% Triton X-100 in PBS; 5% goat serum), incubated in primary antibodies at 4 °C overnight and secondary antibodies for 2 h at room temperature. Hoechst 33,342 (Invitrogen H3570, 1:10,000, 5 min at room temperature) was used to visualize nuclei. Sections were mounted using Fluoromount-G (SouthernBiotech). Images were acquired using Zeiss LSM880 confocal microscope with 20× objective. ZEN Black software was used for image acquisition and ZEN Blue used for Airy processing.
Immunoblotting
Tissues were quickly dissected in cold HBSS and homogenized in RIPA buffer supplemented with protease and phosphatase inhibitors. The homogenate was centrifuged at maximum speed for 10 min to remove cellular debris. Protein concentration was determined by BCA assay (Thermo Scientific #23227). Samples were denatured in 2% SDS supplemented with 2-Mercaptoethanol by heating at 37°C for 5 min. Equal amounts of proteins were loaded and separated by electrophoresis in a 4–15% gradient polyacrylamide gel (BioRad #1653320) or NuPAGE 4–12% Bis-Tris gel (Invitrogen #NP0322), transferred to a nitrocellulose membrane (250 mA, 1.5 h, on ice), blocked in filtered 5% milk in TBST, incubated with primary antibodies overnight at 4°C followed by HRP conjugated secondary antibodies (1:5,000) for 1 h, and visualized with ECL substrate. For phosphorylated protein analysis, the phospho-proteins were probed first, and then blots were stripped (Thermo Scientific #21059) and re-probed for total proteins. Band intensity was quantified by FIJI.

MRI and CT imaging
Isoflurane anesthetized mice were kept warm with a heating pad. MRIs were obtained with a Bruker BioSpec small animal MRI (7T); T2 image criteria: TE/TR = 60/4000; Ave = 4; RARE = 4; slice thickness = 0.6 mm. CTs were obtained with the Bruker Albira microCT scanner (45 kV, 0.4 mA settings). CT images were analyzed with AMIDE and Slicer software.

Constant aCSF infusion test
Briefly and as previously described, a single catheter coupled with an ICP sensor was implanted into the lateral ventricle of an anesthetized mouse. A syringe pump was used to infuse aCSF through the catheter at a constant rate (4 µL/min) while ICP was simultaneously measured. The Marmarou model of CSF dynamics for constant rate infusions were used to calculate parameters describing CSF dynamics by a non-linear least squares fit of the model to the ICP data. The intracranial compliance coefficient (mL) is the reciprocal of Marmarou’s intracranial elasticity coefficient (mL/C). CSF conductance ((mL/min)/mmHg) is the reciprocal of Marmarou’s resistance to CSF reabsorption/outflow (mmHg/(mL/min)). The coefficients were normalized to the average PBS control value on each acquisition date.

AAVs
Production and purification were performed by University of Pennsylvania (Penn) Vector Core (for AAV-NKCC1: hNKCC1 with CMV promoter, modified from Addgene plasmid # 49077; for AAV-NKCC1_NT51: hNKCC1 with N-terminal mutation to prevent phosphorylation, modified from Addgene plasmid #49061 with the same approach as with AAV-NKCC1) or BCH Viral Core (for AAV-GFP).

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
Animal sex, housing, and disease severity were randomized. Biological replicates (N) were defined as samples from distinct individuals except where it was necessary to pooled samples across multiple individuals to obtain sufficient material to make a measurement. All data were collected from at least 2 independent experiments conducted on different dates, with the same protocols. Sample sizes were informed by estimated mean values from preliminary data and previous studies. At least 4 animals from different litters/cohorts were used for each study. Data analyses were performed in a blinded manner whenever possible. For the blood proteome study, the list of proteins was processed in Perseus 1.6.0, log2-transformed, and proteins with fewer than two peptides (razor) were excluded. Principal component analysis was performed on the samples by an unsupervised hierarchical clustering-based heatmap. A pairwise comparison was realized on each age group, the results depicted with a Volcano plot, and a permutation-based FDR testing correction was applied for the significant proteins. Other statistical analyses were performed with Prism 7. Statistics were calculated and are presented both with and without outliers identified by the ROUT method (Q = 1%). Appropriate statistical tests were used based on the distribution of data, homogeneity of variances, and sample sizes. Most of the analyses were performed using One-way ANOVA or Welch’s unpaired t test. F tests or Bartlett’s tests were used to assess homogeneity of variances between datasets. Parametric tests (t test, ANOVA) were used only if data were normally distributed, and variances were approximately equal. Otherwise, nonparametric alternatives were chosen. Data are presented as mean ± SD. See figure legends for statistical tests and sample sizes for each experiment. p values <0.05 were considered significant (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).